Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine vs Gemcitabine + Docetaxel Consolidation in Stage III NSCLC
NCT00191139Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2003
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Gemcitabine Consolidation with Gemcitabine + Docetaxel Consolidation (2 arms). Primary endpoint: 2-Year Survival. Started Mar 2003; status: completed.
02
Drugs
gemcitabinedocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00191139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191139.